Open access
Aug 2026
Pegtarazimod limits acute graft-versus-host disease mortality and severity in mice and is tolerated in patients.
Pegtarazimod reduced aGVHD in mice by suppressing pro inflammatory neutrophil effector functions and preserving enterocyte integrity and the clinical trial data support tolerability of pegtarazimod in aGVHD patients and further studies are needed to determine efficacy.
Verena Holzmüller, Jana Gawron, Ann-Cathrin Burk et al.
· Journal of Clinical Investig... · 0 citations